Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-78c5997874-lj6df Total loading time: 0 Render date: 2024-11-17T11:25:44.706Z Has data issue: false hasContentIssue false

Chapter 17 - Pharmacological Cosmetic Neurology

Published online by Cambridge University Press:  30 November 2019

By
Erin C. Conrad  and
Anjan Chatterjee
Edited by
Kenneth M. Heilman  and
Stephen E. Nadeau
Kenneth M. Heilman
Affiliation:
University of Florida
Stephen E. Nadeau
Affiliation:
University of Florida
Get access

Summary

“Cosmetic neurology,” also referred to as “cognitive enhancement,” is the practice of enhancing cognition and behavior in healthy people. Although cosmetic neurology often refers to the enhancement of cognition, it can also refer to the enhancement of mood, movement, creativity, social finesse, and other psychological attributes. Cosmetic neurology carries the promise of an improved quality of life and productivity well into old age, as well as potential medical and social perils. In this chapter, we review our understanding of the efficacy of drugs including stimulants and cholinesterase inhibitors that can be used for enhancement. We review their potential benefits to the individual and society. We also place the practice of cosmetic neurology in the context of current cultural norms and outline ethical concerns that this practice generates.

Keywords

pharmacologyenhancementneuroethicsstimulantscognition
Type
Chapter
Information
Cognitive Changes and the Aging Brain , pp. 264 - 277
Publisher: Cambridge University Press
Print publication year: 2019

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Chatterjee, A. Cosmetic neurology: the controversy over enhancing movement, mentation, and mood. Neurology. 2004;63(6):968–74.CrossRefGoogle ScholarPubMed
Chatterjee, A. Cosmetic neurology and cosmetic surgery: parallels, predictions, and challenges. Camb Q Healthc Ethics. 2007;16(2):129–37.CrossRefGoogle ScholarPubMed
Haiken, E. Venus Envy: A History of Cosmetic Surgery. Baltimore: Johns Hopkins University Press; 1997.Google Scholar
Snelders, S, Pieters, T. Speed in the Third Reich: metamphetamine (Pervitin) use and a drug history from below. Soc Hist Med. 2011;24(3):686–99.Google Scholar
Vearrier, D, Greenberg, MI, Miller, SN, Okaneku, JT, Haggerty, DA. Methamphetamine: history, pathophysiology, adverse health effects, current trends, and hazards associated with the clandestine manufacture of methamphetamine. Disease-a-Month. 2012 Feb;58(2):38–89.Google Scholar
Steinkamp, P. Pervitin (methamphetamine) tests, use and misuse in the German Wehrmacht. In: Eckart, WU, editor. Man, Medicine, and the State: The Human Body as an Object of Government Sponsored Medical Research in the 20th Century. Stuttgart: Steiner; 2006, pp. 61–71.Google Scholar
Husain, M, Mehta, MA. Cognitive enhancement by drugs in health and disease. Trends Cogn Sci. 2011 Jan;15(1):28–36.CrossRefGoogle ScholarPubMed
Sostek, AJ, Buchsbaum, MS, Rapoport, JL. Effects of amphetamine on vigilance performance in normal and hyperactive children. J Abnorm Child Psychol. 1980 Dec;8(4):491–500.Google Scholar
Koelega, HS. Stimulant drugs and vigilance performance: a review. Psychopharmacology. 1993;111(1):1–16.CrossRefGoogle ScholarPubMed
Pigeau, R, Naitoh, P, Buguet, A, McCann, C, Baranski, J, Taylor, M, et al. Modafinil, d-amphetamine and placebo during 64 hours of sustained mental work. I. Effects on mood, fatigue, cognitive performance and body temperature. J Sleep Res. 1995;4(4):212–28.CrossRefGoogle ScholarPubMed
Baranski, JV, Pigeau, R, Dinich, P, Jacobs, I. Effects of modafinil on cognitive and meta-cognitive performance. Hum Psychopharm Clin. 2004 Jul;19(5):323–32.Google Scholar
Elliott, R, Sahakian, BJ, Matthews, K, Bannerjea, A, Rimmer, J, Robbins, TW. Effects of methylphenidate on spatial working memory and planning in healthy young adults. Psychopharmacology. 1997 May;131(2):196–206.Google Scholar
Bagot, KS, Kaminer, Y. Efficacy of stimulants for cognitive enhancement in non-attention deficit hyperactivity disorder youth: a systematic review. Addiction. 2014 Apr;109(4):547–57.Google Scholar
Breitenstein, C, Wailke, S, Bushuven, S, Kamping, S, Zwitserlood, P, Ringelstein, EB, et al. D-amphetamine boosts language learning independent of its cardiovascular and motor arousing effects. Neuropsychopharmacology. 2004 Sep;29(9):1704–14.Google Scholar
Repantis, D, Schlattmann, P, Laisney, O, Heuser, I. Modafinil and methylphenidate for neuroenhancement in healthy individuals: a systematic review. Pharmacol Res. 2010 Sep;62(3):187–206.Google Scholar
Franke, AG, Gränsmark, P, Agricola, A, Schühle, K, Rommel, T, Sebastian, A, et al. Methylphenidate, modafinil, and caffeine for cognitive enhancement in chess: a double-blind, randomised controlled trial. Eur Neuropsychopharmacol. 2017 Mar;27(3):248–60.CrossRefGoogle Scholar
Franke, AG, Lieb, K. Pharmacological neuroenhancement: substances and epidemiology. In: Hildt, E, Franke, AG, editors. Cognitive Enhancement: An Interdisciplinary Perspective. Dordrecht: Springer Netherlands; 2013, pp. 17–27.CrossRefGoogle Scholar
Fond, G, Micoulaud-Franchi, J-A, Brunel, L, Macgregor, A, Miot, S, Lopez, R, et al. Innovative mechanisms of action for pharmaceutical cognitive enhancement: a systematic review. Psychiatry Res. 2015;229(1):12–20.CrossRefGoogle ScholarPubMed
Winblad, B, Engedal, K, Soininen, H, Verhey, F, Waldemar, G, Wimo, A, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology. 2001 Aug 14;57(3):489–95.Google Scholar
Wesnes, KA, McKeith, IG, Ferrara, R, Emre, M, Del Ser, T, Spano, PF, et al. Effects of rivastigmine on cognitive function in dementia with Lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system. Dement Geriatr Cogn Disord. 2002;13(3):183–92.Google Scholar
Rowan, E, McKeith, IG, Saxby, BK, O’Brien, JT, Burn, D, Mosimann, U, et al. Effects of donepezil on central processing speed and attentional measures in Parkinson’s disease with dementia and dementia with Lewy bodies. Dement Geriatr Cogn Disord. 2007;23(3):161–7.CrossRefGoogle ScholarPubMed
Ferreira-Vieira, TH, Guimaraes, IM, Silva, FR, Ribeiro, FM. Alzheimer’s disease: targeting the cholinergic system. Curr Neuropharmacol. 2016;14(1):101–15.Google Scholar
Repantis, D, Laisney, O, Heuser, I. Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: a systematic review. Pharmacol Res. 2010 Jun;61(6):473–81.Google Scholar
FitzGerald, DB, Crucian, GP, Mielke, JB, Shenal, BV, Burks, D, Womack, KB, et al. Effects of donepezil on verbal memory after semantic processing in healthy older adults. Cogn Behav Neurol. 2008 Jun;21(2):57–64.CrossRefGoogle ScholarPubMed
Yesavage, JA, Mumenthaler, MS, Taylor, JL, Friedman, L, O’Hara, R, Sheikh, J, et al. Donepezil and flight simulator performance: effects on retention of complex skills. Neurology. 2002 Jul 9;59(1):123–5.Google Scholar
Chuah, LYM, Chee, MWL. Cholinergic augmentation modulates visual task performance in sleep-deprived young adults. J Neurosci. 2008 Oct 29;28(44):11369–77.Google Scholar
Chuah, LYM, Chong, DL, Chen, AK, Rekshan, WR 3rd, Tan, J-C, Zheng, H, et al. Donepezil improves episodic memory in young individuals vulnerable to the effects of sleep deprivation. Sleep. 2009 Aug;32(8):999–1010.CrossRefGoogle Scholar
Reisberg, B, Doody, R, Stöffler, A, Schmitt, F, Ferris, S, Möbius, HJ. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med. 2003 Apr 3;348(14):1333–41.Google Scholar
Rammsayer, TH. Effects of pharmacologically induced changes in NMDA-receptor activity on long-term memory in humans. Learn Mem. 2001;8(1):20–5.Google Scholar
Watfa, G, Rossignol, P, Kearney-Schwartz, A, Fay, R, Bracard, S, Felblinger, J, et al. Use of calcium channel blockers is associated with better cognitive performance in older hypertensive patients with subjective memory complaints. J Hypertens. 2010 Dec;28(12):2485–93.Google Scholar
Rose, SPR. “Smart drugs”: do they work? Are they ethical? Will they be legal? Nat Rev Neurosci. 2002 Dec;3(12):975–9.Google Scholar
Ng, TP, Feng, L, Yap, KB, Lee, TS, Tan, CH, Winblad, B. Long-term metformin usage and cognitive function among older adults with diabetes. J Alzheimers Dis. 2014;41(1):61–8.Google Scholar
Luchsinger, JA, Ma, Y, Christophi, CA, Florez, H, Golden, SH, Hazuda, H, et al. Metformin, lifestyle intervention, and cognition in the Diabetes Prevention Program Outcomes Study. Diabetes Care. 2017 Jul;40(7):958–65.Google Scholar
Solomon, PR, Adams, F, Silver, A, Zimmer, J, DeVeaux, R. Ginkgo for memory enhancement: a randomized controlled trial. JAMA. 2002 Aug 21;288(7):835–40.Google Scholar
Birks, J, Grimley, Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. 2007;2:CD003120.Google Scholar
Calabrese, C, Gregory, WL, Leo, M, Kraemer, D, Bone, K, Oken, B. Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: a randomized, double-blind, placebo-controlled trial. J Altern Complement Med. 2008 Jul;14(6):707–13.Google Scholar
Flicker, L, Evans, JG. Piracetam for dementia or cognitive impairment. Cochrane Database Syst Rev. 2001;2:CD001011.Google Scholar
Ng, T-P, Chiam, P-C, Lee, T, Chua, H-C, Lim, L, Kua, E-H. Curry consumption and cognitive function in the elderly. Am J Epidemiol. 2006 Nov 1;164(9):898–906.CrossRefGoogle ScholarPubMed
Solon, O. Meet the Silicon Valley-ites taking tiny hits of LSD to boost performance. Wired. 2016 Aug 24.Google Scholar
Johnstad, PG. Powerful substances in tiny amounts: an interview study of psychedelic microdosing. Nordic Studies on Alcohol and Drugs. 2018;35(1):39–51.Google Scholar
Franke, AG, Bagusat, C, Rust, S, Engel, A, Lieb, K. Substances used and prevalence rates of pharmacological cognitive enhancement among healthy subjects. Eur Arch Psychiatry Clin Neurosci. 2014 Nov;264(Suppl 1):S83–S90.Google Scholar
Singh, I, Bard, I, Jackson, J. Robust resilience and substantial interest: a survey of pharmacological cognitive enhancement among university students in the UK and Ireland. PLoS ONE. 2014 Oct 30;9(10):e105969.Google Scholar
Dietz, P, Striegel, H, Franke, AG, Lieb, K, Simon, P, Ulrich, R. Randomized response estimates for the 12-month prevalence of cognitive-enhancing drug use in university students. Pharmacotherapy. 2013 Jan;33(1):44–50.Google Scholar
Babcock, Q, Byrne, T. Student perceptions of methylphenidate abuse at a public liberal arts college. J Am Coll Health. 2000 Nov;49(3):143–5.Google Scholar
McCabe, SE, Knight, JR, Teter, CJ, Wechsler, H. Non-medical use of prescription stimulants among US college students: prevalence and correlates from a national survey. Addiction. 2005 Jan;100(1):96–106.Google Scholar
Arria, AM, O’Grady, KE, Caldeira, KM, Vincent, KB, Wish, ED. Nonmedical use of prescription stimulants and analgesics: associations with social and academic behaviors among college students. J Drug Issues. 2008;38(4):1045–60.Google Scholar
Arria, AM, Wilcox, HC, Caldeira, KM, Vincent, KB, Garnier-Dykstra, LM, O’Grady, KE. Dispelling the myth of “smart drugs”: cannabis and alcohol use problems predict nonmedical use of prescription stimulants for studying. Addict Behav. 2013 Mar;38(3):1643–50.Google Scholar
Emanuel, RM, Frellsen, SL, Kashima, KJ, Sanguino, SM, Sierles, FS, Lazarus, CJ. Cognitive enhancement drug use among future physicians: findings from a multi-institutional census of medical students. J Gen Intern Med. 2013 Aug;28(8):1028–34.Google Scholar
Franke, AG, Bagusat, C, Dietz, P, Hoffmann, I, Simon, P, Ulrich, R, et al. Use of illicit and prescription drugs for cognitive or mood enhancement among surgeons. BMC Med. 2013 Apr 9;11(1):102.Google Scholar
Caballero, J, Ownby, RL, Rey, JA, Clauson, KA. Cognitive and performance enhancing medication use to improve performance in poker. J Gambl Stud. 2016 Sep;32(3):835–45.CrossRefGoogle ScholarPubMed
Dietz, P, Soyka, M, Franke, AG. Pharmacological neuroenhancement in the field of economics – poll results from an online survey. Front Psychol. 2016 Apr 19;7:520.Google Scholar
Franke, AG, Heinrich, I, Lieb, K, Fellgiebel, A. The use of Ginkgo biloba in healthy elderly. Age. 2014;36(1):435–44.Google Scholar
Arria, AM, Caldeira, KM, Vincent, KB, O’Grady, KE, Cimini, MD, Geisner, IM, et al. Do college students improve their grades by using prescription stimulants nonmedically? Addict Behav. 2017 Feb;65:245–9.CrossRefGoogle ScholarPubMed
Baranski, JV, Pigeau, RA. Self-monitoring cognitive performance during sleep deprivation: effects of modafinil, d-amphetamine and placebo. J Sleep Res. 1997 Jun;6(2):84–91.Google Scholar
Sharp, C. Cognitive enhancers – performance or problem? Occup Med. 2016 Mar;66(2):88–9.Google Scholar
Dekkers, W, Rikkert, MO. Memory enhancing drugs and Alzheimer’s disease: enhancing the self or preventing the loss of it? Med Health Care Philos. 2007;10(2):141–51.Google Scholar
Arce, E, Ehlers, MD. The mind bending quest for cognitive enhancers. Clinical Pharmacology & Therapeutics. 2017;101(2):179–81.Google Scholar
Brand, R, Wolff, W, Ziegler, M. Drugs as instruments: describing and testing a behavioral approach to the study of neuroenhancement. Front Psychol. 2016 Aug 17;7:1226.Google Scholar
Chatterjee, A. Framing pains, pills, and professors. Expositions. 2008;2(2):139–46.Google Scholar
Brignell, CM, Rosenthal, J, Curran, HV. Pharmacological manipulations of arousal and memory for emotional material: effects of a single dose of methylphenidate or lorazepam. J Psychopharmacol. 2007 Sep;21(7):673–83.Google Scholar
Pitman, RK, Sanders, KM, Zusman, RM, Healy, AR, Cheema, F, Lasko, NB, et al. Pilot study of secondary prevention of posttraumatic stress disorder with propranolol. Biol Psychiatry. 2002 Jan 15;51(2):189–92.CrossRefGoogle ScholarPubMed
Clewis, RR. Does Kantian ethics condone mood and cognitive enhancement? Neuroethics. 2017;10(3):349–61.Google Scholar
Schaefer, GO, Kahane, G, Savulescu, J. Autonomy and enhancement. Neuroethics. 2014;7(2):123–36.Google Scholar
Harada, CN, Love, MCN, Triebel, KL. Normal cognitive aging. Clin Geriatr Med. 2013 Nov;29(4):737–52.Google Scholar
English, V, Sommerville, A. Boosting Your Brainpower, Ethical Aspects of Cognitive Enhancements: A Discussion Paper. London: British Medical Association; 2007.Google Scholar
Lucke, J, Partridge, B. Towards a smart population: a public health framework for cognitive enhancement. Neuroethics. 2013;6(2):419–27.Google Scholar
Maslen, H, Santoni de Sio, F, Faber, N. With cognitive enhancement comes great responsibility? In: Koops, B-J, Oosterlaken, I, Romijn, H, Swierstra, T, van den Hoven, J, editors. Responsible Innovation 2. Cham: Switzerland: Springer International Publishing; 2015, pp. 121–38.Google Scholar
Batéjat, DM, Lagarde, DP. Naps and modafinil as countermeasures for the effects of sleep deprivation on cognitive performance. Aviat Space Environ Med. 1999 May;70(5):493–8.Google Scholar
Lerner, BH. A case that shook medicine. Washington Post. 2006 Nov 28.Google Scholar
Lerner, BH. A life-changing case for doctors in training. New York Times. 2009 Mar 3.Google Scholar
Chandler, JA, Dodek, AM. Cognitive enhancement in the courtroom. In: Jotterand, F, Dubljevic, V, editors. Cognitive Enhancement: Ethical and Policy Implications in International Perspectives. New York: Oxford University Press; 2016, pp. 329–45.CrossRefGoogle Scholar
Grunstein, RR, Banerjee, D. The case of “Judge Nodd” and other sleeping judges – media, society, and judicial sleepiness. Sleep. 2007;30(5):625–32.Google Scholar
Danziger, S, Levav, J, Avnaim-Pesso, L. Extraneous factors in judicial decisions. Proc Natl Acad Sci. 2011 Apr 26;108(17):6889–92.Google Scholar
Weinshall-Margel, K, Shapard, J. Overlooked factors in the analysis of parole decisions. Proc Natl Acad Sci U S A. 2011 Oct 18;108(42):E833.Google Scholar
Rachlinski, JJ, Johnson, SL, Wistrich, AJ, Guthrie, C. Does unconscious bias affect trial judges? Notre Dame Law Review. 2009;84(3):1195–246.Google Scholar
Persson, I, Savulescu, J. The perils of cognitive enhancement and the urgent imperative to enhance the moral character of humanity. J Appl Philos. 2008;25(3):162–77.Google Scholar
Hoffman, P. The Man Who Loved Only Numbers: The Story of Paul Erdos and the Search for Mathematical Truth. New York: Hyperion; 1998.Google Scholar
Carter, S. Could moral enhancement interventions be medically indicated? Health Care Anal. 2017 Dec;25(4):338–53.Google Scholar
Douglas, T. Moral enhancement. J Appl Philos. 2008 Aug;25(3):228–45.Google Scholar
Shook, JR. Neuroethics and the possible types of moral enhancement. AJOB Neurosci. 2012;3(4):3–14.Google Scholar
Ahlskog, R. Moral enhancement should target self-interest and cognitive capacity. Neuroethics. 2017 Apr 26;10(3):363–73.Google Scholar
Harris, J. Moral enhancement and freedom. Bioethics. 2010;25(2):102–11.Google Scholar
Kirsch, I. The Emperor’s New Drugs: Exploding the Antidepressant Myth. New York: Basic Books; 2009.Google Scholar
Rutherford, BR, Mori, S, Sneed, JR, Pimontel, MA, Roose, SP. Contribution of spontaneous improvement to placebo response in depression: a meta-analytic review. J Psychiatr Res. 2012 Jun;46(6):697–702.Google Scholar
Benedetti, F. Mechanisms of placebo and placebo-related effects across diseases and treatments. Annu Rev Pharmacol Toxicol. 2008;48:33–60.Google Scholar
Ilieva, I, Boland, J, Farah, MJ. Objective and subjective cognitive enhancing effects of mixed amphetamine salts in healthy people. Neuropharmacology. 2013 Jan;64:496–505.CrossRefGoogle ScholarPubMed
Ioannidis, JPA. Why most published research findings are false. PLoS Med. 2005 Aug;2(8):e124.Google Scholar
Button, KS, Ioannidis, JPA, Mokrysz, C, Nosek, BA, Flint, J, Robinson, ESJ, et al. Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci. 2013 May;14(5):365–76.Google ScholarPubMed
Wilens, TE, Hammerness, PG, Biederman, J, Kwon, A, Spencer, TJ, Clark, S, et al. Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2005 Feb;66(2):253–9.Google Scholar
Nissen, SE. ADHD drugs and cardiovascular risk. N Engl J Med. 2006;354(14):1445–8.CrossRefGoogle ScholarPubMed
Habel, LA, Cooper, WO, Sox, CM, Arnold Chan, K, Fireman, BH, Arbogast, PG, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA. 2011;306(24):2673–83.Google Scholar
Cooper, WO, Habel, LA, Sox, CM, Arnold Chan, K, Arbogast, PG, Craig Cheetham, T, et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med. 2011;365(20):1896–904.Google Scholar
Busardò, FP, Kyriakou, C, Cipolloni, L, Zaami, S, Frati, P. From clinical application to cognitive enhancement: the example of methylphenidate. Curr Neuropharmacol. 2016;14(1):17–27.Google Scholar
Biederman, J, Monuteaux, MC, Spencer, T, Wilens, TE, Macpherson, HA, Faraone, SV. Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study. Am J Psychiatry. 2008 May;165(5):597–603.Google Scholar
Barkley, RA, Fischer, M, Smallish, L, Fletcher, K. Does the treatment of attention-deficit/hyperactivity disorder with stimulants contribute to drug use/abuse? A 13-year prospective study. Pediatrics. 2003 Jan;111(1):97–109.Google Scholar
Brühl, AB, Sahakian, BJ. Drugs, games, and devices for enhancing cognition: implications for work and society. Ann N Y Acad Sci. 2016 Apr;1369(1):195–217.Google Scholar
Banjo, OC, Nadler, R, Reiner, PB. Physician attitudes towards pharmacological cognitive enhancement: safety concerns are paramount. PLoS ONE. 2010 Dec 14;5(12):e14322.Google Scholar
Partridge, BJ, Bell, SK, Lucke, JC, Yeates, S, Hall, WD. Smart drugs “as common as coffee”: media hype about neuroenhancement. PLoS ONE. 2011 Nov 30;6(11):e28416.Google Scholar
Schermer, M. Changes in the self: the need for conceptual research next to empirical research. Am J Bioeth. 2009 May;9(5):45–7.Google Scholar
Shanker, T, Duenwald, M. Threats and responses: military; bombing error puts a spotlight on pilots’ pills. New York Times. 2003 Jan 19.Google Scholar
Schermer, M, Bolt, I, de Jongh, R, Olivier, B. The future of psychopharmacological enhancements: expectations and policies. Neuroethics. 2009;2(2):75–87.Google Scholar
Davis, NJ. A taxonomy of harms inherent in cognitive enhancement. Front Hum Neurosci. 2017 Feb 14;11. ArtID: 63.Google Scholar
Heilman, KM, Nadeau, SE, Beversdorf, DO. Creative innovation: possible brain mechanisms. Neurocase. 2003 Oct;9(5):369–79.Google Scholar
Beversdorf, DQ, Hughes, JD, Steinberg, BA, Lewis, LD, Heilman, KM. Noradrenergic modulation of cognitive flexibility in problem solving. Neuroreport. 1999 Sep 9;10(13):2763–7.Google Scholar
Farah, MJ, Haimm, C, Sankoorikal, G, Smith, ME, Chatterjee, A. When we enhance cognition with Adderall, do we sacrifice creativity? A preliminary study. Psychopharmacology. 2009 Jan;202(1–3):541–7.Google Scholar
Fukuyama, F. Our Posthuman Future: Consequences of the Biotechnology Revolution. New York: Farrar, Straus and Giroux; 2002.Google Scholar
Daniels, N. Normal functioning and the treatment-enhancement distinction. Camb Q Healthc Ethics. 2000 Summer;9(3):309–22.Google Scholar
Reiner, PB. Distinguishing between restoration and enhancement in neuropharmacology. Virtual Mentor. 2010 Nov 1;12(11):885–8.Google Scholar
Caviola, L, Faber, NS. Pills or push-ups? Effectiveness and public perception of pharmacological and non-pharmacological cognitive enhancement. Front Psychol. 2015;6:1852.Google Scholar
Scheske, C, Schnall, S. The ethics of “smart drugs”: moral judgments about healthy people’s use of cognitive-enhancing drugs. Basic Appl Soc Psych. 2012;34(6):508–15.Google Scholar
Specker, J, Schermer, MHN, Reiner, PB. Public attitudes towards moral enhancement. Evidence that means matter morally. Neuroethics. 2017 Jul 27;10(3):405–17.Google Scholar
Bergström, LS, Lynöe, N. Enhancing concentration, mood and memory in healthy individuals: an empirical study of attitudes among general practitioners and the general population. Scand J Public Health. 2008 Jul;36(5):532–7.Google Scholar
Kudlow, PA, Naylor, KT, Xie, B, McIntyre, RS. Cognitive enhancement in Canadian medical students. J Psychoactive Drugs. 2013 Sep;45(4):360–5.Google Scholar
Greely, H, Sahakian, B, Harris, J, Kessler, RC, Gazzaniga, M, Campbell, P, et al. Towards responsible use of cognitive-enhancing drugs by the healthy. Nature. 2008;456(7223):702–5.Google Scholar
Bostrom, N, Sandberg, A. Cognitive enhancement: methods, ethics, regulatory challenges. Sci Eng Ethics. 2009 Sep;15(3):311–41.Google Scholar
Kass, LR. Ageless bodies, happy souls: biotechnology and the pursuit of perfection. The New Atlantis. 2003 Spring;1(1):9–28.Google Scholar
President’s Council on Bioethics (U.S.), Kass, L. Beyond Therapy: Biotechnology and the Pursuit of Happiness. New York: Harper Perennial; 2003.Google Scholar
Elliot, C. American bioscience meets the American dream. Am Prospect. 2003;14(6):38.Google Scholar
Appel, JM. When the boss turns pusher: a proposal for employee protections in the age of cosmetic neurology. J Med Ethics. 2008 Aug;34(8):616–18.Google Scholar
Enck, GG. Pharmaceutical enhancement and medical professionals. Med Health Care Philos. 2014 Feb;17(1):23–8.Google Scholar
Ray, KS. Not just “study drugs” for the rich: stimulants as moral tools for creating opportunities for socially disadvantaged students. Am J Bioeth. 2016;16(6):29–38.Google Scholar
Graf, WD, Nagel, SK, Epstein, LG, Miller, G, Nass, R, Larriviere, D. Pediatric neuroenhancement: ethical, legal, social, and neurodevelopmental implications. Neurology. 2013 Mar 26;80(13):1251–60.Google Scholar
Cakic, V. Smart drugs for cognitive enhancement: ethical and pragmatic considerations in the era of cosmetic neurology. J Med Ethics. 2009 Oct;35(10):611–15.Google Scholar
Klayman, A. Take Your Pills. Netflix; 2018.Google Scholar
Sattler, S, Sauer, C, Mehlkop, G, Graeff, P. The rationale for consuming cognitive enhancement drugs in university students and teachers. PLoS ONE. 2013 Jul 17;8(7):e68821.Google Scholar
Lucke, J, Partridge, B, Forlini, C, Racine, E. Using neuropharmaceuticals for cognitive enhancement: policy and regulatory issues. In: Clausen, J, Levy, N, editors. Handbook of Neuroethics. Dordrecht: Springer Netherlands; 2014, pp. 1085–100.Google Scholar
Shook, JR, Galvagni, L, Giordano, J. Cognitive enhancement kept within contexts: neuroethics and informed public policy. Front Syst Neurosci. 2014 Dec 5;8:228.CrossRefGoogle ScholarPubMed
Synofzik, M. Ethically justified, clinically applicable criteria for physician decision-making in psychopharmacological enhancement. Neuroethics. 2009;2(2):89–102.Google Scholar
Bostrom, N. Drugs can be used to treat more than disease. Nature. 2008;451(7178):520.Google Scholar
Ravelingien, A, Braeckman, J, Crevits, L, De Ridder, D, Mortier, E. “Cosmetic neurology” and the moral complicity argument. Neuroethics. 2009;2(3):151–62.Google Scholar
Ott, R, Lenk, C, Miller, N, Neuhaus Bühler, R, Biller-Andorno, N. Neuroenhancement – perspectives of Swiss psychiatrists and general practitioners. Swiss Med Wkly. 2012 Nov 27;142:w13707.Google Scholar
Hotze, TD, Shah, K, Anderson, EE, Wynia, MK. “Doctor, would you prescribe a pill to help me … ?” a national survey of physicians on using medicine for human enhancement. Am J Bioeth. 2011 Jan;11(1):3–13.Google Scholar
Outram, SM, Racine, E. Developing public health approaches to cognitive enhancement: an analysis of current reports. Public Health Ethics. 2011;4(1):93–105.Google Scholar
Heinz, A, Kipke, R, Heimann, H, Wiesing, U. Cognitive neuroenhancement: false assumptions in the ethical debate. J Med Ethics. 2012 Jun;38(6):372–5.Google Scholar
Zohny, H. The myth of cognitive enhancement drugs. Neuroethics. 2015;8(3):257–69.Google Scholar
Schelle, KJ, Faulmüller, N, Caviola, L, Hewstone, M. Attitudes toward pharmacological cognitive enhancement – a review. Front Syst Neurosci. 2014 Apr 17;8:53.Google Scholar
Bell, S, Partridge, B, Lucke, J, Hall, W. Australian university students’ attitudes towards the acceptability and regulation of pharmaceuticals to improve academic performance. Neuroethics. 2013;6(1):197–205.Google Scholar
Aikins, RD. Academic performance enhancement: a qualitative study of the perceptions and habits of prescription stimulant–using college students. J Coll Stud Dev. 2011;52(5):560–76.Google Scholar
Desantis, AD, Hane, AC. “Adderall is definitely not a drug”: justifications for the illegal use of ADHD stimulants. Subst Use Misuse. 2010;45(1–2):31–46.Google Scholar
Dodge, T, Williams, KJ, Marzell, M, Turrisi, R. Judging cheaters: is substance misuse viewed similarly in the athletic and academic domains? Psychol Addict Behav. 2012 Sep;26(3):678–82.Google Scholar
Fitz, NS, Nadler, R, Manogaran, P, Chong, EWJ, Reiner, PB. Public attitudes toward cognitive enhancement. Neuroethics. 2014;7(2):173–88.CrossRefGoogle Scholar
Franke, AG, Bonertz, C, Christmann, M, Engeser, S, Lieb, K. Attitudes toward cognitive enhancement in users and nonusers of stimulants for cognitive enhancement: a pilot study. AJOB Prim Res. 2012;3(1):48–57.Google Scholar
Franke, AG, Lieb, K, Hildt, E. What users think about the differences between caffeine and illicit/prescription stimulants for cognitive enhancement. PLoS ONE. 2012;7(6):e40047.Google Scholar
Partridge, B, Bell, S, Lucke, J, Hall, W. Australian university students’ attitudes towards the use of prescription stimulants as cognitive enhancers: perceived patterns of use, efficacy and safety. Drug Alcohol Rev. 2013;32(3):295–302.Google Scholar
Partridge, B, Lucke, J, Hall, W. A comparison of attitudes toward cognitive enhancement and legalized doping in sport in a community sample of Australian adults. AJOB Prim Res. 2012;3(4):81–6.Google Scholar
Sabini, J, Monterosso, J. Judgments of the fairness of using performance enhancing drugs. Ethics Behav. 2005;15(1):81–94.Google Scholar
Sattler, S, Forlini, C, Racine, É, Sauer, C. Impact of contextual factors and substance characteristics on perspectives toward cognitive enhancement. PLoS ONE. 2013;8(8):e71452.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×